
Opinion|Videos|December 18, 2024
Overview of Frontline Luspatercept in LR-MDS
Author(s)Guillermo Garcia-Manero, MD, David Swoboda, MD
Panelists discuss how frontline luspatercept is emerging as an effective treatment for anemia in lower-risk myelodysplastic syndrome (LR-MDS), demonstrating significant improvements in hemoglobin levels and transfusion independence, as supported by clinical trial data.
Episodes in this series






































